Fatal Disseminated Candidiasis Due to Amphotericin-B-Resistant Candida guilliermondii

  1. JAMES D. DICK, Ph.D.;
  2. BRUCE R. ROSENGARD, B.S.;
  3. WILLIAM G. MERZ, Ph.D.;
  4. ROBERT K. STUART, M.D.;
  5. GROVER M. HUTCHINS, M.D.; and
  6. REIN SARAL, M.D.
  1. The Johns Hopkins Medical Institutions;
    Baltimore, Maryland

    Excerpt

    Disseminated candidiasis is a significant cause of morbidity and mortality in immunocompromised patients. Candida albicans is the commonest pathogen associated with systemic candidiasis, although other species do cause infections (1). Amphotericin B is the drug of choice for treatment of disseminated candidal infection, and the development of amphotericin B resistance is considered rare. We report the case of a patient with aplastic anemia who died from disseminated infection caused by a strain of C. guilliermondii that developed progressive resistance to amphotericin B.

    A 52-year-old white woman was admitted to The Johns Hopkins Oncology Center for evaluation and treatment of aplastic

    Acknowledgments

    ACKNOWLEDGMENTS: Grant support: in part by grants CA 06973 and CA 15396-08 from the National Cancer Institute, National Institutes of Health; and by a grant from the Harley W. Howell Foundation.

    Article and Author Information

    • ▸Requests for reprints should be addressed to James D. Dick, Ph.D.; Department of Laboratory Medicine, The Johns Hopkins Hospital, 600 N. Wolfe Street; Baltimore, MD 21205.

    « Previous | Next Article »Table of Contents